FRCPC

ASDS/A Board of Directors Appoints Tara Azzano as Executive Director

Retrieved on: 
Monday, April 8, 2024
Research, Diagnosis, Executive, Patient, Association management, FRCPC, Society, Interim, Meeting, ASDS, Medicine, Management

Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.

Key Points: 
  • Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.
  • She joined the organization in 2002 as the Director of Education, Research and Meetings.
  • Azzano has almost a quarter of a century’s worth of experience with ASDS/A, and her institutional knowledge of our Society is unprecedented.
  • “I am truly thrilled to have been chosen as the next Executive Director and to continue to share my passion for dermatologic surgery.

The START Center for Cancer Research Takes a Major Step Forward in its Mission to Bring the Hope of Cancer Research to Communities Globally

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, ChromeOS, FJD, MBE, Growth, Environment, Patient, Pi, Cancer, EMA, MD, FRCPC, START, PDX, Clinical trial, Safety, Multimedia, Principal investigator, FDA, Physician, Pharmaceutical industry

The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.

Key Points: 
  • The START Center for Cancer Research, the world's largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally.
  • Slack, a respected leader in the clinical research industry, brings nearly 20 years of experience to grow START's mission of revolutionizing cancer clinical research.
  • With a global network spanning eight locations, including START San Antonio, START Midwest, START Mountain Region, START Madrid (FJD and CIOCC), START Barcelona, START Dublin, and START Lisbon, START is at the forefront of advancing cancer research.
  • Co-founders of The START Center for Cancer Research, Amita Patnaik, MD, FRCPC, and Kyriakos P. Papadopoulos, MD, will continue their pivotal roles as Co-directors of Clinical Research at START San Antonio.

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Retrieved on: 
Thursday, March 7, 2024
EDT, Master of Science, MD, Diabetic neuropathy, Notalgia paresthetica, FRCPC, Therapy, Webcast, Patient, Diagnosis, Itch, Epidemiology, KOL

The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).

Key Points: 
  • The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).
  • The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics.
  • The event will also highlight oral difelikefalin in NP and its potential in this underserved neuropathy.
  • A live webcast of the event will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com .

Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis

Retrieved on: 
Tuesday, February 20, 2024
Health Canada, Denosumab, RANK, Biosimilar, Safety, FRCPC, Novartis, Patient, Osteoporosis, Generic drug

Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.

Key Points: 
  • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass.
  • Health Canada approval based on robust Phase I and Phase III clinical studies.
  • BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia*).
  • Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

Children’s Hospital Los Angeles Unveils New Fetal Cardiac Clinic

Retrieved on: 
Tuesday, February 13, 2024
Nursing, Cardiology, Children, Baby, Maternity, Health, General Health, Family, Hospitals, Surgery, Consumer, Parenting, Master of Science, Division, CHLA, Multimedia, MSN, RN, Magnetic resonance imaging, CCRN, Ventricular septal defect, Pregnancy, Learning, Child, Risk, MHA, FRCPC, Circulant matrix, MHO, Patient, Senior counsel, Social, Heart, Diagnosis, Test management, MRI, Hospital

Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.

Key Points: 
  • Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240213588362/en/
    The Heart Institute at Children's Hospital Los Angeles celebrates the opening of its new Fetal Cardiac Clinic.
  • “With the launch of our new Fetal Cardiac Clinic, we now have a dedicated space that can serve as a one-stop shop for families in need of comprehensive prenatal diagnostic testing and counseling for cardiac anomalies.”
    CHLA’s state-of-the-art Fetal Cardiac Clinic features over 3,000 square feet of space and three scanning rooms dedicated to fetal cardiology.
  • Services provided at the CHLA Fetal Cardiac Clinic include:
    To learn more about CHLA’s Fetal Cardiac Clinic, visit CHLA.org/FetalCardiology or call 323-361-7398.

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Knowledge, School, Chronic pain, Hospital, Faculty, Patient, FRCPC, Public health, Toronto General Hospital, Advisory Committee, Knowledge translation, Medical school, Entrepreneurship, Queen Elizabeth, Consortium, Assistant, Pain management, Drug development, Risk, Anesthesiology, Toronto Centre, Doctor of Philosophy, University, Committee, Medicine, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.
  • Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care.
  • "We are pleased to announce the appointment of Dr. Hance Clarke to the Clinical Advisory Committee," said Brent Zettl, President and CEO of the Company.
  • This strategic addition to our Clinical Advisory Committee reaffirms ZYUS’ commitment to advancing non-opioid-based therapies as a viable alternative for managing pain.”
    "I am honored to join ZYUS’ Clinical Advisory Committee and eager to contribute to ZYUS’ important work.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Psychiatry, Quality of life, Medication discontinuation, GEMINI, Evolve, Depression, University, DSM-IV codes, Therapy, Drug, Quality, FRCPC, Annual general meeting, CNS, American College, University of Toronto, EVOLVE, Central nervous system, MDD, Anxiety, Grammatical mood, ASCEND, Pharmaceutical industry

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points: 
  • New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
    NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
  • These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
  • An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
  • “Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation

Retrieved on: 
Thursday, December 21, 2023
Biology, MTR, Dermatitis, DOI, Hospital, Atopic dermatitis, Protein, FAAD, Family, Immune system, Division, Neuron, Sensation, Allergy, British Columbia Children's Hospital, Research, Cell, DRS, University of British Columbia, Sol, Disease, Tissue, Mouse, Rheumatoid arthritis, Cancer, Inflammation, Asthma, FRCPC, University, JAK, Mutation, Faculty, Hypereosinophilic syndrome, Nervous system, Gene, Lung, MBBS, Neuroinflammation, Patient, JAK1, Medical school, Diagnosis, Canada Research Chair, STAT6, Signal, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues. Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders. Details on the findings were published in the December 21, 2023, issue of the journal Cell (DOI: 10.1016/j.cell.2023.11.027).

Key Points: 
  • Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
  • Current JAK inhibitors work well against inflammation in diseases like eczema, but the study suggests a need for a nuanced approach in modulating JAK activity for conditions like asthma.
  • The study showed that activated JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, where it suppresses lung inflammation.
  • In the lung neurons of the mice, the JAK1 mutant protein reduced inflammation caused by exposure to mold by producing substances that suppress inflammation.